GlassScriptPhysician profile
Alfred L Knable
NPI 1174538912
$202,690.93
in general payments reported to CMS, 2019-2025
37 companies · $21K in 2025
The $21K reported for 2025 was more than what 94% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $94K · 2020: $11K · 2021: $13K · 2022: $26K · 2023: $20K · 2024: $18K · 2025: $21K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $50K · Food and Beverage: $6,490 · Travel and Lodging: $2,507 · Education: $255.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $49,750.00 |
| Food and Beverage | $6,490.35 |
| Travel and Lodging | $2,507.19 |
| Education | $255.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $156,866.46 | 2019-2025 | |
| Pfizer INC. | $34,129.70 | 2019-2023 | |
| Journey Medical Corporation | $4,680.17 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $1,496.73 | 2019-2025 | |
| Janssen Biotech, INC. | $790.73 | 2021-2025 | Tremfya |
| Lilly USA, LLC | $622.65 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Ucb, INC. | $614.02 | 2019-2025 | Bimzelx |
| Regeneron Healthcare Solutions, INC. | $565.42 | 2019-2025 | Dupixent, Libtayo |
| E.R. Squibb & Sons, L.L.C. | $446.80 | 2021-2025 | Sotyktu |
| Galderma Laboratories, L.P. | $370.84 | 2019-2025 | Aklief, Epsolay, Twyneo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $331.57 | 2022-2025 | Spevigo, Cyltezo |
| Amgen INC. | $245.15 | 2019-2024 | Otezla |
| Incyte Corporation | $244.44 | 2021-2025 | Opzelura |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $185.34 | 2019-2025 | Siliq, Jublia, Cabtreo |
| Sun Pharmaceutical Industries INC. | $180.89 | 2020-2025 | Absorica Ld, Winlevi |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $155.25 | 2019-2025 | |
| Celgene Corporation | $130.09 | 2019 | |
| Epi Health, LLC | $103.41 | 2019-2022 | |
| Dermavant Sciences, INC. | $64.12 | 2022-2023 | Vtama |
| Prugen, INC. Pharmaceuticals | $49.37 | 2019 | |
| Revance Therapeutics, INC. | $47.15 | 2024 | Daxxify |
| Genentech USA, INC. | $42.79 | 2021-2022 | |
| Botanix Sb INC | $35.61 | 2025 | Sofdra |
| Mayne Pharma Commercial LLC | $35.35 | 2019 | |
| Dermira, INC. | $33.36 | 2020 | |
| Arcutis Biotherapeutics, INC. | $32.27 | 2023 | |
| Blueprint Medicines Corporation | $22.10 | 2023 | |
| Organon LLC | $21.86 | 2025 | Vtama |
| Leo Pharma INC. | $20.89 | 2025 | Anzupgo |
| Vyne Pharmaceuticals INC. | $19.03 | 2021 | |
| Almirall LLC | $18.52 | 2021 | |
| Kyowa Kirin, INC. | $17.76 | 2024 | Poteligeo |
| Biofrontera INC. | $15.96 | 2021 | |
| Convatec INC. | $15.47 | 2024 | |
| Nabriva Therapeutics, Plc | $15.34 | 2022 | |
| Taro Pharmaceuticals USA, INC. | $12.35 | 2019 | |
| Helsinn Therapeutics (U.S.), INC. | $11.97 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alfred Knable listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.